Association of serum TRAIL level with coronary artery disease
Authors:
- 1 April 2010
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 125 (4) , 322-325
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathwayOncogene, 2008
- Expression, regulation and function of trail in atherosclerosisBiochemical Pharmacology, 2008
- TRAIL and osteoprotegerin: a role in endothelial physiopathology?Frontiers in Bioscience-Landmark, 2008
- Insulin down‐regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitroJournal of Cellular Physiology, 2007
- Trail and vascular injuryFrontiers in Bioscience-Landmark, 2007
- Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosisAtherosclerosis, 2006
- TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and releaseBlood, 2005
- The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosisJACC, 2005
- Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) Sequentially Upregulates Nitric Oxide and Prostanoid Production in Primary Human Endothelial CellsCirculation Research, 2003
- Inflammation in atherosclerosisNature, 2002